Mesothelioma patients who received Tumor Treating Fields with pemetrexed and cisplatin or carboplatin experienced median overall survival of 18.2 months compared to 12.1 months in historical control with no increase in systemic toxicity Data will be highlighted in an oral presentation at world’s largest meeting dedicated to lung cancer and other thoracic malignancies ST. HELIER, …

Zai Lab granted license to commercialize oncology platform technology Tumor Treating Fields, including the brand name Optune®, in China, Hong Kong, Macau and Taiwan Zai Lab will support enrollment of Chinese patients to certain clinical trials investigating Tumor Treating Fields, intended to accelerate clinical trial enrollment Tumor Treating Fields currently marketed in the U.S., the …

Mesothelioma patients who received Tumor Treating Fields with pemetrexed and cisplatin or carboplatin experienced median overall survival of 18.2 months compared to 12.1 months in historical control with no increase in systemic toxicity Results support the use of Tumor Treating Fields in first potential indication outside of the brain Company to host analyst and investor …